Close Menu

NEW YORK – Startup Savran Technologies aims to detect disease recurrence in triple negative breast cancer (TNBC) patients with its microfluidic platform, which isolates and quantifies circulating tumor cells (CTCs). The company believes the method could complement circulating tumor DNA (ctDNA)-based approaches to monitor for minimal residual disease (MRD).  

Savran Technologies expects to integrate the microfluidic chip with a ctDNA assay offered by a liquid biopsy partner, with a goal to launch the combined platform in the US by 2022.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.